A jab well done: On India’s Human Papillomavirus vaccination programme

India’s move to introduce a nationwide Human Papillomavirus (HPV) vaccination programme, for girls aged 14, strikes a strident note for science at a time when an anti-vaccination sentiment has perilously picked up favourable winds, globally. The impact of shunning vaccines is apparent in the United States where, currently, a measles epidemic is making its way across 26 States. The HPV vaccination will be conducted exclusively at designated government health facilities, and in the presence of trained medical officers, supported by skilled health-care teams equipped for post-vaccination observation and management of adverse events following immunisation (AEFI). A single-dose vaccine, a regimen recommended by the World Health Organization, will be deployed. Adequate evidence exists to show that almost all cases of cervical cancer are caused by persistent infection with high-risk types of HPV, particularly 16 and 18. These two types together account for more than 80% of cervical cancer cases in India. Evidence also points to the fact that cervical cancer is largely preventable through HPV vaccination and regular screening, and can be cured if detected early and treated promptly. Globally, over 90 countries are implementing single-dose HPV vaccination schedules. Several countries have demonstrated substantial reductions in HPV infection, pre-cancerous lesions, and cervical cancer incidence following widespread vaccination. Cervical cancer remains a rare cancer where a vaccine has proven to be of great preventive value.

The sheer burden of cervical cancer in India is what makes this decision a critical life-saving intervention: The South-East Asia Region (SEARO) accounts for the second-highest cervical cancer incident (new cases) and death rate among WHO regions, with India contributing over 65% of the burden. The second most common cancer in women in India, it was estimated that the country had 127,526 new cases and 79,906 deaths from cervical cancer in 2022. National screening coverage remains alarmingly low, with only 1.9% of women aged 30-49 being tested. However, India’s dark past with an HPV vaccine trial cannot be forgotten. Seven girls who were part of a trial in 2009-10 in Andhra Pradesh and Gujarat died. An ICMR investigation averred that the reasons “were most probably unrelated to the vaccine. However, the cause of death in all the cases cannot be established with certainty”. It also flagged, as a key concern, the need to identify and investigate all AEFI. As the government embarks on this exercise that could lead to many health gains, it will do well to ensure a working cold chain to store the vaccines, complete transparency, and meticulous reporting of AEFI across the country.

Overall Analysis

This editorial strongly supports India’s decision to introduce a nationwide Human Papillomavirus (HPV) vaccination programme for 14-year-old girls. It frames the move as a scientifically sound and timely intervention, especially in a global climate where anti-vaccination sentiment is gaining traction. By contrasting India’s proactive stance with the measles resurgence in the United States, the editorial highlights the consequences of vaccine hesitancy and positions India’s policy as responsible public health governance.

The first paragraph emphasizes the scientific basis of the programme. It details the structured rollout — administration at government facilities, trained medical staff, monitoring of adverse events following immunisation (AEFI), and adoption of the single-dose regimen recommended by the World Health Organization. The editorial uses evidence-based language, citing the strong link between high-risk HPV types (16 and 18) and cervical cancer. The tone here is confident and reassuring, presenting vaccination as both safe and effective. By noting that over 90 countries have adopted similar schedules, the editorial reinforces the global consensus behind the move.

The second paragraph shifts focus to India’s domestic burden. It underscores the gravity of cervical cancer statistics, especially within the WHO South-East Asia Region (SEARO), where India accounts for the majority of cases. The use of concrete numbers — new cases and deaths — strengthens the urgency of the intervention. The editorial also points out alarmingly low screening rates, implying that vaccination becomes even more critical in a system where preventive screening is inadequate.

However, the piece does not ignore past controversies. It refers to the 2009–10 HPV vaccine trial deaths in Andhra Pradesh and Gujarat, acknowledging public mistrust. By mentioning the investigation by the Indian Council of Medical Research (ICMR), which found no confirmed causal link but stressed careful monitoring, the editorial balances optimism with caution. The closing lines advocate for transparency, a strong cold chain system, and meticulous AEFI reporting. This ensures credibility and safeguards public trust.

Overall, the editorial blends scientific validation, statistical urgency, and ethical accountability. It endorses the vaccination drive while reminding the government that trust and transparency are as crucial as medical efficacy.

Important Vocabulary (5)

1. Strident – loud and forceful; strongly expressed.
2. Perilously – in a way that involves serious risk or danger.
3. Regimen – a prescribed course of medical treatment.
4. Averred – stated or declared confidently as a fact.
5. Meticulous – showing great attention to detail; very careful.

Conclusion & Tone

The editorial concludes that India’s HPV vaccination programme is a scientifically justified and potentially life-saving intervention, particularly given the high burden of cervical cancer. At the same time, it stresses the importance of transparency, safety monitoring, and logistical preparedness to maintain public confidence.

Tone: Supportive, evidence-based, and cautiously optimistic — combining scientific endorsement with responsible scrutiny.